Zacks: Analysts Anticipate BIOLINERX LTD/S (BLRX) to Announce -$0.05 EPS
Wall Street brokerages expect BIOLINERX LTD/S (NASDAQ:BLRX) to post earnings of ($0.05) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for BIOLINERX LTD/S’s earnings, with the lowest EPS estimate coming in at ($0.05) and the highest estimate coming in at ($0.04). BIOLINERX LTD/S also posted earnings per share of ($0.05) during the same quarter last year. The company is expected to announce its next earnings report on Monday, August 12th.
According to Zacks, analysts expect that BIOLINERX LTD/S will report full year earnings of ($0.17) per share for the current fiscal year, with EPS estimates ranging from ($0.19) to ($0.15). For the next financial year, analysts expect that the business will post earnings of ($0.18) per share, with EPS estimates ranging from ($0.21) to ($0.15). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for BIOLINERX LTD/S.
BIOLINERX LTD/S (NASDAQ:BLRX) last released its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05).
Several institutional investors and hedge funds have recently bought and sold shares of the company. Two Sigma Securities LLC bought a new stake in BIOLINERX LTD/S during the fourth quarter valued at about $25,000. Deutsche Bank AG bought a new stake in BIOLINERX LTD/S during the fourth quarter valued at about $26,000. Menta Capital LLC bought a new stake in BIOLINERX LTD/S during the fourth quarter valued at about $33,000. Delek Group Ltd. bought a new stake in BIOLINERX LTD/S during the first quarter valued at about $92,000. Finally, ETF Managers Group LLC boosted its position in BIOLINERX LTD/S by 79.4% during the fourth quarter. ETF Managers Group LLC now owns 375,909 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 166,386 shares in the last quarter. 35.86% of the stock is currently owned by institutional investors and hedge funds.
BLRX stock traded down $0.02 during midday trading on Thursday, reaching $0.36. The company’s stock had a trading volume of 38,811 shares, compared to its average volume of 1,179,674. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.18. BIOLINERX LTD/S has a 1 year low of $0.35 and a 1 year high of $1.84. The firm has a market cap of $42.00 million, a price-to-earnings ratio of -1.75 and a beta of 1.63.
BIOLINERX LTD/S Company Profile
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Recommended Story: What is a conference call?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.